The global leader in developing LAG-3 therapeutics
2018 Summary
• Strong operational and financial progress
• Continued focus on LAG-3 immunotherapy
• Progressed the development of four LAG-3 based product candidates for cancer and auto immune disease
• Reported encouraging interim data for lead product candidate, IMP321 (‘efti’) from TACTI-mel trial
• Committed partnerships with five of the world’s largest pharmaceutical companies - Merck (MSD), Novartis and GSK, plus Merck (Germany) and Pfizer, along with Eddingpharm (EOC) in China
To view Presentation please download PDF attached:
Download this document
